Drug Trial Radar · NCT07673887
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
570
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Feb 28, 2031
Study completion Feb 28, 2031
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with gastric cancer (also known as stomach cancer) or gastroesophageal junction cancer (GEJ cancer). GEJ is where the tube that carries food (esophagus) joins the stomach. This study is for people with gastric or GEJ cancer that has spread nearby (locally advanced) and is not removable by surgery (unresectable), or has spread to other parts of the body (metastatic). It is for those whose cancer is human epidermal growth factor receptor 2 (HER2)-negative and CLDN18.2-positive. HER2-negative means the cancer does not have extra HER2 protein, so medicines that target HER2 do not work and are therefore not used. CLDN18.2-positive means people have a certain amount of CLDN18.2 proteins on their cancer cells. In this study, researchers want to learn if ASP2138 given together with standard treatments (chemotherapy and pembrolizumab) help people with HER2-negative and CLDN18.2-positive gastric or GEJ cancer. The main aim is to learn how long people who are given ASP2138 with chemotherapy and pembrolizumab live without their cancer getting worse, compared with placebo given with chemotherapy with or without pembrolizumab, and if they live for longer. Placebo looks like the study treatment but does not have any medicine in it. The main aim of this study is to check how well ASP2138 works when given together with chemotherapy and pembrolizumab compared with placebo plus chemotherapy with or without pembrolizumab. People aged 18 years or older with locally advanced unresectable or metastatic gastric or GEJ cancer can take part. Their tumor should be HER2-negative and CLDN18.2-positive. The study doctors will check people for any health conditions that can exclude them from taking part, interfere with the study procedures, or pose an unacceptable risk. This is a double-blind study. That means the people and the study doctors will not know who will receive which treatment. People will be assigned to one of 2 treatment groups by chance: Group A: People will receive ASP2138 along with chemotherapy and pembrolizumab. Group B: People will receive placebo along with chemotherapy, with or without pembrolizumab. People will keep receiving treatment until their cancer gets worse, they have medical problems that require stopping treatment, or a study rule says they must stop. There will be regular safety checks. People will continue to have scans of their tumor until their cancer becomes worse.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
ASP2138Drug
SC Injection
PembrolizumabDrug
IV Infusion
OxaliplatinDrug
IV Infusion
CapecitabineDrug
Oral administration
Folinic acidDrug
IV Infusion
5-FUDrug
IV Infusion or IV bolus
Placebo for ASP2138Drug
SC Injection
Placebo for PembrolizumabDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 54 months
- Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST V1.1) by Blinded Independent Central Review (BICR)Time frame: Up to 54 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota · Recruiting
Sun Yat-Sen University Cancer Center - Huangpu Campus
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer
Guangzhou, Guangzhou, China · Recruiting
Niigata Cancer Center Hospital
Niigata, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan · Recruiting
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, Japan · Recruiting
Hyogo Cancer Center
Akashi, Hyōgo, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Pan American Center for Oncology Trials
Dorado, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.